Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.58 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.58 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | EDNRB | P24530 | 2/20 | 0.40 |
| ▸ | EDNRA | P25101 | 2/20 | 0.40 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | CASP6 | P55212 | 1/20 | 0.38 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.38 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.36 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716381 | 1.00 | KDM1A (0.58) | KDM1AKDM1BCYP4F2CYP4A11DGAT1 | |
| SCHEMBL14690279 | 0.87 | KDM1A (0.42) | KDM1AKDM1BCYP4F2CYP4A11DGAT1 | |
| SCHEMBL17003046 | 0.87 | KDM1A (0.42) | KDM1AKDM1BCYP4F2CYP4A11DGAT1 | |
| SCHEMBL15541789 | 0.83 | HTR2A (0.49) | KDM1AKDM1BCYP4F2CYP4A11TDP1 | |
| SCHEMBL11902614 | 0.83 | HTR2A (0.49) | KDM1AKDM1BCYP4F2CYP4A11TDP1 | |
| SCHEMBL11902326 | 0.83 | HTR2A (0.49) | KDM1AKDM1BCYP4F2CYP4A11TDP1 | |
| SCHEMBL17385720 | 0.82 | CYP4F2 (0.44) | KDM1AKDM1BCYP4F2CYP4A11FFAR1 | |
| SCHEMBL4714304 | 0.82 | KDM1A (0.53) | KDM1AKDM1BDGAT1TDP1L3MBTL1 | |
| SCHEMBL4717194 | 0.82 | KDM1A (0.53) | KDM1AKDM1BDGAT1TDP1L3MBTL1 | |
| SCHEMBL5643859 | 0.82 | KDM1A (0.53) | KDM1AKDM1BDGAT1ALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836180-B1 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI SA (FR) | 2012-06-13 | — | — | EP | disclosed |
| US-20090105479-A1 | 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same | MERCK & CO., INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20090105479-A1 | 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same | MERCK & CO., INC. (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080070940-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | DUBE DANIEL | 2008-03-20 | — | — | US | disclosed |
| US-20080070940-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | DUBE DANIEL | 2008-03-20 | — | — | US | disclosed |
| EP-1836180-A2 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | sanofi-aventis (FR) | 2007-09-26 | — | — | EP | disclosed |
| EP-1633306-A4 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO INC (US) | 2007-05-16 | — | — | EP | disclosed |
| WO-2007048225-A1 | A 4-OXO-1- (3-SUBSTITUTED PHENYL) -1, 4-DIHYDRO-1, 8-NAPHTHYRIDINE-3-CARBOXAMIDE PHOSPHODIESTERASE-4-INHIBITOR AND A METHOD OF PREPARING SAME | MERCK FROSST CANADA LTD. (CA) | 2007-05-03 | — | — | WO | disclosed |
| WO-2007050576-A2 | A METHOD OF PREPARING A 4-OXO-1- (3 SUBSTITUTED PHENYL) -1, 4-DIHYDRO-1, 8-NAPHTHYRIDINE-3- CARBOXAMIDE PHOSPHODIESTERASE-4 INHIBITOR | MERCK & CO., INC. (US) | 2007-05-03 | — | — | WO | disclosed |
| US-20070099951-A1 | 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | DUBE DANIEL | 2007-05-03 | — | — | US | disclosed |
| US-20070099951-A1 | 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | DUBE DANIEL | 2007-05-03 | — | — | US | disclosed |
| WO-2006072393-A2 | SULFONYL PYRROLIDINES, METHOD FOR PRODUCING THE SAME AND THEIR USE AS DRUGS | SANOFI-AVENTIS (DE) | 2006-07-13 | — | — | WO | disclosed |
| EP-1633306-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | Merck & Co., Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004105698-A2 | USE OF PHOSPHATASE INHIBITORS AS ADJUNCT THERAPY FOR PSYCHIATRIC DISORDERS | MERCK & CO., INC. (US) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099951-A1 | 4-oxo-1-(3-substituted phenyl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | PDE4A, PDE12, PDE4B | KDM1A 713/4885KDM1B 1337/4885CYP4F2 177/4885 |
| US-20080070940-A1 | 4-Oxo-1-(3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor and a method of preparing same | PDE4A, PDE12, PDE4B | KDM1A 613/4885KDM1B 1290/4885CYP4F2 163/4885 |
| US-20090105479-A1 | 4-Oxo-1-3-Substituted Phenyl-1,4-Dihydro-1,8-Napthyridene-3-Carboxamide Phosphodiesterase-4 Inhibitor and a Method of Preparing Same | PDE12, PDE4A, PDE4B | KDM1A 694/4885KDM1B 1532/4885CYP4F2 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.